Letter from the management

This quarter we achieved key steps in our growing commercial business in Europe, while moving earlier-stage R&D programs forward. We are confident that we are positioning Galapagos for future growth. Onno van de Stolpe, CEO

We are excited to bring Jyseleca as a new treatment option to patients living with rheumatoid arthritis, and we report on sales achieved with our own commercial organization. Due to acceleration of our savings program, we reduce our full year 2021 operational cash burn guidance by €50 million to €530 to €570 million. Bart Filius, President & COO